백순명
#병리학#종양학#유전체학
|
학력
1975-1977: 연세대학교 의예과
1977-1981: 연세대학교 의과대학 의사 의학
1977-1981: 연세대학교 의과대학 의사 의학
경력
1983-1985: Shadyside Hospital / Resident
1985-1986: State University of New York Health Science Center at Brooklyn/ Resident
1986-1987: State University of New York Health Science Center at Brooklyn/
Subspecialty Resident in Neuropathology
1987-1988: Medicine Branch, National Cancer Institute/ Senior Staff Fellow
1988-1990: Lombardi Cancer Center, Georgetown University/ Post-docoral fellow
1990-1995: Lombardi Cancer Center, Georgetown Universtiy/ Assistant Professor
1995-1999: Pathology Section, NSABP/ Co-Director
1999.6.1.～present: Division of Pathology, NSABP Foundation/ Director
2009-2012: Samsung Cancer Research Institute, Samsung Medical Center/ Director
1985-1986: State University of New York Health Science Center at Brooklyn/ Resident
1986-1987: State University of New York Health Science Center at Brooklyn/
Subspecialty Resident in Neuropathology
1987-1988: Medicine Branch, National Cancer Institute/ Senior Staff Fellow
1988-1990: Lombardi Cancer Center, Georgetown University/ Post-docoral fellow
1990-1995: Lombardi Cancer Center, Georgetown Universtiy/ Assistant Professor
1995-1999: Pathology Section, NSABP/ Co-Director
1999.6.1.～present: Division of Pathology, NSABP Foundation/ Director
2009-2012: Samsung Cancer Research Institute, Samsung Medical Center/ Director
논문
1: Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG, Fumagalli D,Goldstein LC, Sneige N, Burandt E, Taniyama Y, Bohn OL, Lee A, Kim SI, Reilly ML, Remillard MY, Blackmon NL, Kim SR, Horne ZD, Rastogi P, Fehrenbacher L, RomondEH, Swain SM, Mamounas EP, Wickerham DL, Geyer CE Jr, Costantino JP, Wolmark N, Paik S. Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP TrialB-31. J Natl Cancer Inst. 2013 Nov 21. [Epub ahead of print] PubMed PMID:24262440.
2: Pogue-Geile K, Yothers G, Taniyama Y, Tanaka N, Gavin P, Colangelo L, BlackmonN, Lipchik C, Kim SR, Sharif S, Allegra C, Petrelli N, O'Connell MJ, Wolmark N,Paik S. Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. J Natl Cancer Inst. 2013 Jul 3;105(13):989-92. PubMed PMID: 23821759
3: Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, Cronin MT, Watson D, Shak S, Bohn OL, Fumagalli D, Taniyama Y, Lee A, Reilly ML, Vogel VG, McCaskill-Stevens W, Ford LG, Geyer CE Jr, Wickerham DL, Wolmark N, Paik S. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in thetreatment and prevention of estrogen receptor-positive breast cancer. J ClinOncol. 2011 Nov 1;29(31):4160-7. PubMed PMID: 21947828
4: Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation ofprognostic and predictive biomarkers. J Natl Cancer Inst. 2009 Nov4;101(21):1446-52. PubMed PMID:19815849.
5: Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab inbreast cancer. N Engl J Med. 2008 Mar 27;358(13):1409-11. PubMed PMID: 18367751.
6: Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D,Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N. Gene expressionand benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006 Aug 10;24(23):3726-34. PubMed PMID: 16720680.
7: Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. Amultigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004 Dec 30;351(27):2817-26. PubMed PMID:15591335.
Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 105/Issue :1782-1788,2013
Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 105/13 :989-992,2013
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
LANCET 384/9938 :164-172,2014
Nanomaterials for theranostics: Recent advances and future challenges
CHEMICAL REVIEWS 115/1 :327-394,2015
Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
CLINICAL CANCER RESEARCH 21/3 :544-552,2015
Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine
YONSEI MEDICAL JOURNAL 56/5 :1186-1198,2015
Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial
JOURNAL OF CLINICAL ONCOLOGY 33/12 :1340-1347,2015
A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2
BREAST CANCER RESEARCH AND TREATMENT 149/2 :517-523,2015
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): Secondary outcomes of a phase 3, randomised controlled trial
LANCET ONCOLOGY 16/9 :1037-1048,2015
Prognostic tests for estrogen receptor-positive breast cancer: Need for global consideration and further evolution
JAMA oncology 3/- :E1-E3,2015
Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
MOLECULAR CANCER THERAPEUTICS 14/10 :2238-2248,2015
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
NEW ENGLAND JOURNAL OF MEDICINE 373/21 :2005-2014,2015
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
ONCOTARGET 6/42 :44971-44984,2015
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
NEW ENGLAND JOURNAL OF MEDICINE 374/3 :211-222,2016
Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.
Oncogenesis 5/7 :e241-,2016
Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative
ONCOTARGET 7/17 :24,172-24,178,2016
EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines
MOLECULAR CANCER THERAPEUTICS 15/7 :1,627-1,636,2016
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes Secondary Analysis of NSABP C-O7/NRG Oncology Randomized Clinical Trial
JAMA Oncology 2/9 :1162-1169,2016
Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer
BREAST CANCER RESEARCH AND TREATMENT 163/2 :255-262,2017
Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
ONCOTARGET 8/24 :39,367-39,381,2017
Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.
ANNALS OF ONCOLOGY 28/6 :1,250-1,259,2017
Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer
ONCOTARGET 8/24 :38,389-38,398,2017
21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 109/4 :1-8,2017
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40
ANNALS OF SURGICAL ONCOLOGY 24/7 :1,853-1,860,2017
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in
ADVANCES IN ANATOMIC PATHOLOGY 24/5 :235-251,2017
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial
JAMA oncology 3/3 :335-341,2017
AIRVF: a filtering toolbox for precise variant calling in Ion Torrent sequencing
BIOINFORMATICS 34/7 :1,232-1,234,2018
Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information
ANNALS OF ONCOLOGY 29/4 :1,030-1,036,2018
Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells with Markers of the Epithelial?Mesenchymal Transition, Due to Loss of NAPRT
GASTROENTEROLOGY 155/3 :799-814,2018
Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth
GENOME RESEARCH 28/3 :374-382,2018
Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
LUNG CANCER 124/ :168-178,2018
Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology)
BRITISH JOURNAL OF CANCER 118/5 :629-633,2018
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
NEW ENGLAND JOURNAL OF MEDICINE 379/2 :111-121,2018
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology
BREAST CANCER RESEARCH AND TREATMENT 168/1 :69-77,2018
Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab
PHARMACOGENETICS AND GENOMICS 28/6 :147-152,2018
Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations
PLOS ONE 13/8 :e0200836-,2018
Bcl-2-dependent synthetic lethal interaction of the IDF-11774 with the V0 subunit C of vacuolar ATPase (ATP6V0C) in colorectal cancer
BRITISH JOURNAL OF CANCER 119/11 :1,347-1,357,2018
Use of letrozole after aromatase inhibitor-based therapy (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled phase 3 trial
LANCET ONCOLOGY 20/1 :88-99,2019
A therapeutic strategy for chemotherapy-resistant gastric cancer via destabilization of both β-catenin and ras
Cancers 11/4 :496-1-496-16,2019
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
NEW ENGLAND JOURNAL OF MEDICINE 380/25 :2,395-2,405,2019
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 111/8 :867-871,2019
2: Pogue-Geile K, Yothers G, Taniyama Y, Tanaka N, Gavin P, Colangelo L, BlackmonN, Lipchik C, Kim SR, Sharif S, Allegra C, Petrelli N, O'Connell MJ, Wolmark N,Paik S. Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. J Natl Cancer Inst. 2013 Jul 3;105(13):989-92. PubMed PMID: 23821759
3: Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, Cronin MT, Watson D, Shak S, Bohn OL, Fumagalli D, Taniyama Y, Lee A, Reilly ML, Vogel VG, McCaskill-Stevens W, Ford LG, Geyer CE Jr, Wickerham DL, Wolmark N, Paik S. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in thetreatment and prevention of estrogen receptor-positive breast cancer. J ClinOncol. 2011 Nov 1;29(31):4160-7. PubMed PMID: 21947828
4: Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation ofprognostic and predictive biomarkers. J Natl Cancer Inst. 2009 Nov4;101(21):1446-52. PubMed PMID:19815849.
5: Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab inbreast cancer. N Engl J Med. 2008 Mar 27;358(13):1409-11. PubMed PMID: 18367751.
6: Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D,Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N. Gene expressionand benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006 Aug 10;24(23):3726-34. PubMed PMID: 16720680.
7: Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. Amultigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004 Dec 30;351(27):2817-26. PubMed PMID:15591335.
Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 105/Issue :1782-1788,2013
Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 105/13 :989-992,2013
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
LANCET 384/9938 :164-172,2014
Nanomaterials for theranostics: Recent advances and future challenges
CHEMICAL REVIEWS 115/1 :327-394,2015
Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
CLINICAL CANCER RESEARCH 21/3 :544-552,2015
Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine
YONSEI MEDICAL JOURNAL 56/5 :1186-1198,2015
Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial
JOURNAL OF CLINICAL ONCOLOGY 33/12 :1340-1347,2015
A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2
BREAST CANCER RESEARCH AND TREATMENT 149/2 :517-523,2015
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): Secondary outcomes of a phase 3, randomised controlled trial
LANCET ONCOLOGY 16/9 :1037-1048,2015
Prognostic tests for estrogen receptor-positive breast cancer: Need for global consideration and further evolution
JAMA oncology 3/- :E1-E3,2015
Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
MOLECULAR CANCER THERAPEUTICS 14/10 :2238-2248,2015
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
NEW ENGLAND JOURNAL OF MEDICINE 373/21 :2005-2014,2015
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
ONCOTARGET 6/42 :44971-44984,2015
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
NEW ENGLAND JOURNAL OF MEDICINE 374/3 :211-222,2016
Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.
Oncogenesis 5/7 :e241-,2016
Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative
ONCOTARGET 7/17 :24,172-24,178,2016
EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines
MOLECULAR CANCER THERAPEUTICS 15/7 :1,627-1,636,2016
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes Secondary Analysis of NSABP C-O7/NRG Oncology Randomized Clinical Trial
JAMA Oncology 2/9 :1162-1169,2016
Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer
BREAST CANCER RESEARCH AND TREATMENT 163/2 :255-262,2017
Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
ONCOTARGET 8/24 :39,367-39,381,2017
Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.
ANNALS OF ONCOLOGY 28/6 :1,250-1,259,2017
Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer
ONCOTARGET 8/24 :38,389-38,398,2017
21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 109/4 :1-8,2017
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40
ANNALS OF SURGICAL ONCOLOGY 24/7 :1,853-1,860,2017
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in
ADVANCES IN ANATOMIC PATHOLOGY 24/5 :235-251,2017
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial
JAMA oncology 3/3 :335-341,2017
AIRVF: a filtering toolbox for precise variant calling in Ion Torrent sequencing
BIOINFORMATICS 34/7 :1,232-1,234,2018
Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information
ANNALS OF ONCOLOGY 29/4 :1,030-1,036,2018
Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells with Markers of the Epithelial?Mesenchymal Transition, Due to Loss of NAPRT
GASTROENTEROLOGY 155/3 :799-814,2018
Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth
GENOME RESEARCH 28/3 :374-382,2018
Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
LUNG CANCER 124/ :168-178,2018
Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology)
BRITISH JOURNAL OF CANCER 118/5 :629-633,2018
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
NEW ENGLAND JOURNAL OF MEDICINE 379/2 :111-121,2018
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology
BREAST CANCER RESEARCH AND TREATMENT 168/1 :69-77,2018
Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab
PHARMACOGENETICS AND GENOMICS 28/6 :147-152,2018
Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations
PLOS ONE 13/8 :e0200836-,2018
Bcl-2-dependent synthetic lethal interaction of the IDF-11774 with the V0 subunit C of vacuolar ATPase (ATP6V0C) in colorectal cancer
BRITISH JOURNAL OF CANCER 119/11 :1,347-1,357,2018
Use of letrozole after aromatase inhibitor-based therapy (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled phase 3 trial
LANCET ONCOLOGY 20/1 :88-99,2019
A therapeutic strategy for chemotherapy-resistant gastric cancer via destabilization of both β-catenin and ras
Cancers 11/4 :496-1-496-16,2019
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
NEW ENGLAND JOURNAL OF MEDICINE 380/25 :2,395-2,405,2019
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 111/8 :867-871,2019
저서
저서 내용이 없습니다.
보도자료
노형석 노보믹스 사장 "위암 예후진단 키트로 맞춤치료 시대 열 것"
http://v.media.daum.net/v/20200311145857771?f=o
강남세브란스 의생명연구센터, 개소 10주년 심포지엄 개최
http://v.media.daum.net/v/20191202155929511?f=o
[대한민국 名병원] ③ 세브란스병원, 정밀의학에 600억원 투자.....
http://v.media.daum.net/v/20170515110851851?f=o
http://v.media.daum.net/v/20200311145857771?f=o
강남세브란스 의생명연구센터, 개소 10주년 심포지엄 개최
http://v.media.daum.net/v/20191202155929511?f=o
[대한민국 名병원] ③ 세브란스병원, 정밀의학에 600억원 투자.....
http://v.media.daum.net/v/20170515110851851?f=o
포스팅
포스팅 내용이 없습니다.
영상자료
영상자료 내용이 없습니다.
발표자료
발표자료 내용이 없습니다.